KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].
体外研究 (In Vitro)
The inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at concentration of 3.91 uM[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
476.32
Formula
C21H22BrN3O5
CAS 号
744198-19-4
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Sheng Huaying, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048.
[2]. L Yuan, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene
KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].
体外研究 (In Vitro)
The inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at concentration of 3.91 uM[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
476.32
Formula
C21H22BrN3O5
CAS 号
744198-19-4
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Sheng Huaying, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048.
[2]. L Yuan, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene
KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].
体外研究 (In Vitro)
The inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at concentration of 3.91 uM[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
476.32
Formula
C21H22BrN3O5
CAS 号
744198-19-4
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Sheng Huaying, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048.
[2]. L Yuan, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene
KCC-07 是一种有效的,选择性的且可透过血脑屏障的 MBD2 (methyl-CpG-binding domain protein 2) 抑制剂。KCC-07 防止 MBD2 与甲基化 DNA 结合,并激活脑特异性血管生成抑制剂 1 (BAI1) 诱导抗增殖 BAI1/p53/p21 信号传导。抗癌活性。
KCC-07 Chemical Structure
CAS No. : 315702-75-1
规格
价格
是否有货
数量
5 mg
¥850
In-stock
10 mg
¥1500
In-stock
25 mg
¥3000
In-stock
50 mg
¥4800
In-stock
100 mg
¥7500
In-stock
200 mg
询价
500 mg
询价
* Please select Quantity before adding items.
KCC-07 相关产品
•相关化合物库:
Bioactive Compound Library Plus
Cell Cycle/DNA Damage Compound Library
Anti-Cancer Compound Library
CNS-Penetrant Compound Library
Anti-Aging Compound Library
Anti-Lung Cancer Compound Library
Transcription Factor Targeted Library
生物活性
KCC-07 is a potent, selective and brain-penetrant MBD2 (methyl-CpG-binding domain protein 2) inhibitor. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling. Anticancer activity[1].
IC50 & Target
MBD2 (methyl-CpG-binding domain protein 2)[1]
体外研究 (In Vitro)
KCC-07 (10 μM; 72 hours; MB cells) treatment clearly inhibited MB cell growth in vitro, consistent with induction of anti-proliferative BAI1/p53/p21 signaling[1]. KCC-07 (10 μM; 48 hours; MB cells) treatment largely abrogates MBD2 binding to the ADGRB1 promoter and restores BAI1 mRNA and protein expression in BAI1-silent MB cells[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[1]
Cell Line:
Medulloblastomas (MB) cells
Concentration:
10 μM
Incubation Time:
72 hours
Result:
Clearly inhibited MB cell growth in vitro.
Western Blot Analysis[1]
Cell Line:
Medulloblastomas (MB) cells
Concentration:
10 μM
Incubation Time:
48 hours
Result:
Largely abrogated MBD2 binding to the ADGRB1 promoter in BAI1-silent MB cells.
体内研究 (In Vivo)
KCC-07 (100 mg/kg; intraperitoneal injection; 5 days/week; athymic nude mice) treatment inhibits tumor growth and significantly extends the survival of MB xenografts in vivo[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
[1]. Dan Zhu, et al. BAI1 Suppresses Medulloblastoma Formation by Protecting p53 From Mdm2-Mediated Degradation. Cancer Cell. 2018 Jun 11;33(6):1004-1016.e5.